Evaluating neoadjuvant immunotherapy for early stage lung cancer in China

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the effectiveness of neoadjuvant immunotherapy in patients with early-stage non-small cell lung cancer (NSCLC) in China. It will analyze the impact of single-agent immunotherapy and immunotherapy combined with chemotherapy on major pathological response (MPR) and overall survival. Additionally, biomarker analysis will be conducted to tailor immunotherapy approaches for individual patients. The study will include patients with stage II-IIIA NSCLC who meet specific eligibility criteria.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Written informed consent provided
* Males or females aged ≥18 years
* Able to comply with the required protocol and follow-up procedures、
* Pathologically diagnosed of potentially resectable non-small cell lung cancer with stage II-IIIA (TNM 8th edition)
* Measurable disease must be characterized according to RECIST 1.1 criteria
* ECOG performance status 0-1
* Regardless of PD-L1 expression
* EGFR mutation (-) and ALK translocation (-)
* Pulmonary function could be well tolerated by lobectomy or pneumonectomy

Exclusion Criteria:

* EGFR mutation (+) or ALK translocation (+)
* Active Central nervous system (CNS) metastases
* Patients with active, known or suspected autoimmune disease.
* Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement or unexpected conditions of recurrence in the absence of an external trigger are allowed to be included
* Patients with a condition requiring systemic treatment with either corticosteroids (\>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of enrollment
* Inhaled or topical steroids, and adrenal replacement steroid doses \> 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease
* Patients with a history of interstitial lung disease cannot be included if they have symptomatic ILD (Grade 3-4) and/or poor lung function. Patients with other active malignancy requiring concurrent intervention and/ or concurrent treatment with other investigational drugs or anti-cancer therapy
* Patients with previous malignancies (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colon, endometrial, cervical/ dysplasia, melanoma, or breast) are excluded unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required during the study period
* Any medical, mental or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or understand the patient information
* Patients who have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways Patients with positive test for hepatitis B virus surface antigen (HBVsAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating active hepatitis
* Patients with known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) Patients with history of allergy to study drug components excipients
* Women who are pregnant or in the period of breastfeeding
* Sexually active men and women of childbearing potential who are not willing to use an effective contraceptive method during the study
* In case of doubt please contact trial team.

Where it's running

• Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Si-Yang Liu
• Email: momogogogo@126.com
• Phone: 13242305346

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• VSV-02 for advanced solid tumors

  This treatment will try VSV-02 given into a vein and directly into tumors to see if it helps people with advanced solid tumors who have limited treatment options.

  Recruiting Phase 1 The First Affiliated Hospital of Xinxiang Medical College · Xinxiang, Henan · NCT07260591

• Combining targeted therapies for solid tumors using CDK4/6 inhibitors and anti-VEGF agents

  This study is testing if combining two cancer treatments, Palbociclib and Bevacizumab, can help people with solid tumors like colorectal, breast, and ovarian cancers feel better and respond better to treatment.

  Recruiting at 2 sites Phase 1 Lebanese University · Tripoli, North Lebanon and 1 other locations · NCT06307249

• CAR-T cell therapy targeting multiple cancer markers

  This study is testing a new CAR-T cell therapy that aims to help patients with advanced lung cancer and other cancers by using their own modified immune cells to target specific cancer markers.

  Recruiting at 2 sites Phase 1 Second Affiliated Hospital of Guangzhou Medical University · Guangzhou, Guangdong and 1 other locations · NCT03198052

• ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden

  This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.

  Recruiting Tongji Hospital · Hubei, Wuhan · NCT07912190

• MRD-guided postoperative monitoring and adaptive treatment for resectable NSCLC

  This study tests a personalized follow-up and treatment plan using ctDNA MRD testing and pathology to guide adjuvant therapy after surgery for stage IB-IIIA NSCLC treated with neoadjuvant immunotherapy.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07894458

• PULSAR radiotherapy plus immunotherapy for high-risk advanced liver cancer

  This study tests whether adding PULSAR radiotherapy to standard immunotherapy helps adults with high‑risk advanced liver cancer live longer without their cancer progressing.

  Recruiting Phase 2 Samsung Medical Center · Seoul · NCT07884877

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.